References
- Karen CC, John GB. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011;65:501–521.
- Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011;24:370–376.
- Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005;49:3529–3532.
- Freifeld AG, Bow EJ, Sepkowitz KA, . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–e93.
- Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011;53(Suppl. 1):S4–S7.
- Dellit TH, Owens RC, McGowan JE Jr, . Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
- Heard SR, Wren B, Barnett MJ, . Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1988;100:63–72.
- Rampling A, Warren RE, Bevan PC, . Clostridium difficile in haematological malignancy. J Clin Pathol 1985;38:445–451.
- Panichi G, Pantosti A, Gentile G, . Clostridium difficile colitis in leukemia patients. Eur J Cancer Clin Oncol 1985;21:1159–1163.
- Morris JG Jr, Jarvis WR, Nunez-Montiel OL, . Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 1984;144:967–969.
- Hornbuckle K, Chak A, Lazarus HM, . Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998;9:307–311.
- Loo VG, Bourgault AM, Poirier L, . Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693–1703.
- Paul M, Yahav D, Bivas A, . Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010;(11):CD005197.
- von Baum H, Sigge A, Bommer M, . Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58:891–894.
- Slavin MA, Lingaratnam S, Mileshkin L, . Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011;41:102–109.
- Chapin KC, Dickenson RA, Wu F, . Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011;13:395–400.
- Schalk E, Bohr UR, Konig B, . Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009;89:9–14.
- Gorschluter M, Glasmacher A, Hahn C, . Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786–791.